- Home
- NG vs ELVN Comparison
NG vs ELVN Comparison
Compare NG & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NG | ELVN |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NG | ELVN |
|---|---|---|
| Price | $9.80 | $16.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $10.17 | ★ $41.20 |
| AVG Volume (30 Days) | ★ 2.7M | 708.2K |
| Earning Date | 01-22-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.26 | $13.30 |
| 52 Week High | $10.90 | $25.37 |
Technical Indicators
Market Signals| Indicator | NG | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 30.93 |
| Support Level | $9.56 | $16.62 |
| Resistance Level | $10.01 | $20.47 |
| Average True Range (ATR) | 0.41 | 1.43 |
| MACD | -0.02 | -0.56 |
| Stochastic Oscillator | 50.19 | 2.49 |
Price Performance
Historical ComparisonAbout NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other presious metals.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.